Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety.

@article{Heldmann2016ClinicalEW,
  title={Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety.},
  author={Frank Heldmann and Xenofon Baraliakos and Uta Kiltz and J. O. Brandt and Irene Eva van der Horst-Bruinsma and Robert B. M. Landew{\'e} and Joachim Sieper and Gerd ‐ R{\"u}diger Burmester and Filip E van den Bosch and Kurt de Vlam and Hill Gaston and Mathias Gruenke and Matthias Witt and Thierry Appelboom and P T J Emery and Maxime R Dougados and Marjatta Leirisalo-Repo and Maxime Breban and J{\"u}rgen Braun},
  journal={Clinical and experimental rheumatology},
  year={2016},
  volume={34 2},
  pages={184-90}
}
OBJECTIVES Knowledge on the long-term effects of anti-TNF therapy in patients with ankylosing spondylitis (AS) is still limited. Our objective was to study the long-term efficacy and safety of anti-TNF therapy in AS. METHODS After having completed the first part of the EASIC trial a total of 71 patients were enrolled into this 96-week extension study. Patients were treated with the same dosages and dosing intervals of infliximab as in the EASIC core study. Efficacy was assessed by using… CONTINUE READING